acute sinusitis

Telithromycin is a semisynthetic 14-membered macrolide antibiotic and erythromycin derivative that binds to the 50S subunit of the 70S bacterial ribosome, inhibits bacterial protein synthesis, and exhibits antimicrobial activity against a wide range of gram-positive and gram-negative bacteria for the treatment of mild to moderate respiratory infections.

Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is a

Fenspiride hydrochloride (Decaspiride) , an oxazolidinone spiro compound, is a drug used in the therapy of certain respiratory diseases. It is approved for use in Russia for the therapy of chronic and acute inflammatory diseases of ENT organs and the respiratory tract (like sinusitis, tracheobronchitis, otitis, laryngitis, and rhinopharyngitis), and for maintenance therapy of asthma.

Decarboxy Moxifloxacin is a decarboxylated compound of moxifloxacin. Moxifloxacin is an oral active 8-methoxyquinolone antibiotic used in acute bacterial sinusitis, chronic bronchitis, acute bacterial deterioration, and community-acquired pneumonia.

Cefdinir is an advanced broad-spectrum cephalosporin antibacterial compound approved for treating community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis tonsillitis, acute bacterial otitis media, and uncomplicated skin and skin structure infections in both adult and pediatric patients.

Moxifloxacin-d4 hydrochloride (BAY 12-8039-d4) is the hydrochloride salt form of deuterium-labeled Moxifloxacin (Moxifloxacin). This compound acts as an orally effective antibacterial agent and is utilized in research concerning acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and infectious pneumonia.

IDR 1002, an innate defense regulator peptide, effectively diminishes bacterial load and mitigates inflammatory responses in murine models of sinusitis and acute bacterial lung infections. It suppresses LPS-induced activation of NF-κB and COX-2 while promoting the phosphorylation and activation of p38, ERK1/2, MSK1, and CREB.

Cefpodoxime proxetil-d3 is a deuterated compound of Cefpodoxime proxetil. Cefpodoxime proxetil has a CAS number of 87239-81-4. Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.